Hangzhou Alltest Biotech Co., Ltd. (688606.SS)
CNY 65.97
(-0.06%)
CNY 65.97
(-0.06%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 211.58 Million CNY | -85.03% |
| 2022 | 1.39 Billion CNY | 55.43% |
| 2021 | 896.74 Million CNY | 13.12% |
| 2020 | 792.72 Million CNY | 799.74% |
| 2019 | 88.1 Million CNY | 40.89% |
| 2018 | 62.53 Million CNY | 65.56% |
| 2017 | 37.77 Million CNY | 116.3% |
| 2016 | 17.46 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 84.73 Million CNY | -10.54% |
| 2024 Q1 | 47.32 Million CNY | -40.46% |
| 2024 Q2 | 94.72 Million CNY | 100.13% |
| 2023 Q3 | 38.02 Million CNY | -15.16% |
| 2023 FY | 208.59 Million CNY | -85.03% |
| 2023 Q4 | 79.49 Million CNY | 109.05% |
| 2023 Q2 | 44.82 Million CNY | -3.1% |
| 2023 Q1 | 46.25 Million CNY | 122.6% |
| 2022 FY | 1.39 Billion CNY | 55.43% |
| 2022 Q3 | 30.52 Million CNY | -89.64% |
| 2022 Q2 | 294.51 Million CNY | -76.29% |
| 2022 Q1 | 1.24 Billion CNY | 269.54% |
| 2022 Q4 | -204.62 Million CNY | -770.43% |
| 2021 Q1 | 174.34 Million CNY | -50.49% |
| 2021 Q4 | 336.16 Million CNY | 86.37% |
| 2021 Q3 | 180.38 Million CNY | -12.38% |
| 2021 Q2 | 205.85 Million CNY | 18.08% |
| 2021 FY | 896.74 Million CNY | 13.12% |
| 2020 Q4 | 352.12 Million CNY | 384.24% |
| 2020 Q3 | 72.71 Million CNY | -78.0% |
| 2020 Q2 | 330.48 Million CNY | 783.69% |
| 2020 Q1 | 37.39 Million CNY | 111.43% |
| 2020 FY | 792.72 Million CNY | 799.74% |
| 2019 Q4 | 17.68 Million CNY | 0.0% |
| 2019 FY | 88.1 Million CNY | 40.89% |
| 2018 FY | 62.53 Million CNY | 65.56% |
| 2017 FY | 37.77 Million CNY | 116.3% |
| 2016 FY | 17.46 Million CNY | 0.0% |